Citations

Showing 10 of 108152 citations.

Disseminated Blastomycosis Presenting with Spontaneous Coronary Artery Dissection
Sehgal, Rahul , O'Cochlain, D Fearghas, Virata, Andrew, Singh, Gurpreet , Virata, Andrew R, O'Cochlain, D. Fearghas, Singh, Gurpreet

Mayo Clinic

European Journal of Case Reports in Internal Medicine | May 25, 2021 | Volume: 8 | Issue: 4 | Pages: No page available

10.12890/2021_002511 | PMID 33987130 Get It

Spontaneous coronary artery dissection (SCAD) is increasingly recognized as an important cause of acute coronary syndrome (ACS) and myocardial infarction (MI) in individuals with few or no known atherosclerotic risk factors. While systemic autoimmune inflammatory disorders are associated with precipitating SCAD, the role of infection-induced systemic inflammation in SCAD is not well defined. We present the case of a 49-year-old Caucasian woman with ST-elevation myocardial infarction (STEMI) diagnosed as SCAD from a severe systemic inflammatory response related to disseminated blastomycosis. Punch biopsy of a skin lesion and synovial fluid culture confirmed Blastomyces dermatitidis. This case suggests the possibility of systemic infection-induced inflammation as a precipitating factor in SCAD pathogenesis similar to autoimmune inflammatory disorders.
MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease
Chen, Qin , Arani, Arvin , Senjem, Matthew L. , Jack, Clifford R. , Przybelski, Scott A. , Lesnick, Timothy G. , Kremers, Walter K. , Fields, Julie A. , Gunter, Jeffrey L. , Trzasko, Joshua D. , Graff‐Radford, Jonathan, Savica, Rodolfo , Ferman, Tanis J. , Graff‐Radford, Neill R., Petersen, Ronald C. , Kantarci, Kejal , Arani, Arvin , Jack, Clifford R , Senjem, Matthew L , Kantarci, Kejal , Ferman, Tanis J , Kremers, Walter K , Boeve, Bradley F. , Schwarz, Christopher G. , Graff‐Radford, Jonathan , Knopman, David S. , Dickson, Dennis W. , Graff‐Radford, Neill R.

Mayo Clinic

Journal of Neuroimaging | May 25, 2021 | Volume: 31 | Issue: 5 | Pages: 1020-1027

10.1111/jon.12878 | PMID 34033185 Get It

ABSTRACT Background and Purpose Neurodegeneration of the substantia nigra in Lewy body disease is associated with iron deposition, which increases the magnetic susceptibility of the substantia nigra on MRI. Our objective was to measure iron deposition in the substantia nigra in patients with probable dementia with Lewy bodies (pDLB) and patients who are at risk for pDLB by quantitative susceptibility mapping (QSM). Methods Participants included pDLB ( n = 36), mild cognitive impairment with at least one core feature of DLB (MCI‐LB; n = 15), idiopathic rapid eye movement sleep behavior disorder (iRBD; n = 11), and an age‐and gender‐matched clinically unimpaired control group ( n = 102). QSM was derived from multi‐echo 3D gradient recalled echo MRI at 3T, and groups were compared on mean susceptibility values of the substantia nigra and its relation to parkinsonism severity. Results Patients with pDLB had higher susceptibility in the substantia nigra compared to controls ( p < 0.001) and MCI‐LB ( p = 0.043). The susceptibility of substantia nigra showed an increasing trend from controls to iRBD and MCI‐LB, and to pDLB ( p < 0.001). Parkinsonism severity was not associated with the mean susceptibility in the substantia nigra in the patient groups. Conclusions Our data suggested that QSM is sensitive to the increased magnetic susceptibility due to higher iron content in the substantia nigra in pDLB. The trend of increasing susceptibility from controls to iRBD and MCI‐LB, and to pDLB suggests that iron deposition in the substantia nigra starts to increase as early as the prodromal stage in DLB and continues to increase as the disease progresses, independent of parkinsonism severity.
Self-Expandable Transcatheter Aortic Valve Frame Infolding: An Increasingly Recognized Complication
Singh, Gurpreet , Le, Vien , Wiechmann, Robert J., Schreiter, Steven W., Singh, Gurpreet K. , Le, Vien

Mayo Clinic

European Journal of Case Reports in Internal Medicine | May 25, 2021 | Volume: 7 | Issue: 12 | Pages: No page available

10.12890/2020_002100 | PMID 33585329 Get It

Transcatheter aortic valve replacement (TAVR) with either a balloon-expandable or a self-expandable transcatheter heart valve (THV) is an approved therapy for patients with symptomatic severe aortic stenosis and high or intermediate surgical risk. Here we present a case of severe valve frame infolding of a CoreValve Evolut PRO® self-expandable THV (Medtronic Inc.), which was restored to optimal geometry with balloon post-dilation.
Preserved skeletal muscle oxidative capacity in older adults despite decreased cardiorespiratory fitness with ageing
Zhang, Xiaoyan , Kunz, Hawley , Gries, Kevin J. , Hart, Corey R., Kunz, Hawley E., Gries, Kevin, Lanza, Ian R , Kunz, Hawley E , Polley, Eric C. , Lanza, Ian R.

Mayo Clinic

The Journal of Physiology | May 25, 2021 | Volume: 599 | Issue: 14 | Pages: 3581-3592

10.1113/jp281691 | PMID 34032280 Get It

Key points Healthy older adults exhibit lower cardiorespiratory fitness () than young in the absence of any age‐related difference in skeletal muscle mitochondrial capacity, suggesting central haemodynamics plays a larger role in age‐related declines in . Total physical activity did not differ by age, but moderate‐to‐vigorous physical activity was lower in older compared to young adults. Moderate‐to‐vigorous physical activity is associated with and muscle oxidative capacity, but physical inactivity cannot entirely explain the age‐related reduction in . AbstractDeclining fitness () is a hallmark of ageing and believed to arise from decreased oxygen delivery and reduced muscle oxidative capacity. Physical activity is a modifiable lifestyle factor that is critical when evaluating the effects of age on parameters of fitness and energy metabolism. The objective was to evaluate the effects of age and sex on , muscle mitochondrial physiology, and physical activity in young and older adults. An additional objective was to assess the contribution of skeletal muscle oxidative capacity to age‐related reductions in and determine if age‐related variation in and muscle oxidative capacity could be explained on the basis of physical activity levels. In 23 young and 52 older men and women measurements were made of , mitochondrial physiology in permeabilized muscle fibres, and free‐living physical activity by accelerometry. Regression analyses were used to evaluate associations between age and , mitochondrial function, and physical activity. Significant age‐related reductions were observed for (P < 0.001), but not muscle mitochondrial capacity. Total daily step counts did not decrease with age, but older adults showed lower moderate‐to‐vigorous physical activity, which was associated with (R2 = 0.323, P < 0.001) and muscle oxidative capacity (R2 = 0.086, P = 0.011). After adjusting for sex and physical activity, age was negatively associated with but not muscle oxidative capacity. Healthy older adults exhibit lower but preserved mitochondrial capacity compared to young. Physical activity, particularly moderate‐to‐vigorous, is a key factor in observed age‐related changes in fitness and muscle oxidative capacity, but cannot entirely explain the age‐related reduction in .
Clinical Manifestations and Long‐Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America
Doubelt, Irena , Cuthbertson, David , Carette, Simon , Forbess, Lindsy, Koening, Curry L. , Langford, Carol A. , McAlear, Carol A. , Moreland, Larry W. , Springer, Jason , Sreih, Antoine G. , Moreland, Larry W , Monach, Paul A , Spiera, Robert F , Springer, Jason M , Chung, Sharon A. , Khalidi, Nader , Monach, Paul A. , Seo, Philip , Specks, Ulrich , Spiera, Robert , Warrington, Kenneth J. , Merkel, Peter A. , Pagnoux, Christian

Mayo Clinic

ACR Open Rheumatology | May 25, 2021 | Volume: 3 | Issue: 6 | Pages: 404-412

10.1002/acr2.11263 | PMID 34032390 Get It

ObjectiveTo describe clinical manifestations and outcomes in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in North America.MethodsAnalysis of patients aged 18 years or older who fulfilled the 1990 American College of Rheumatology Classification Criteria for EGPA enrolled in the Vasculitis Clinical Research Consortium from 2003 to 2019. Main clinical characteristics, treatments, outcomes, and accumulated damage were studied.ResultsThe cohort included 354 patients; 59% female; age at diagnosis of 50.0 (±14) years; 39% were antineutrophil cytoplasm antibody (ANCA) positive. Time from diagnosis to last follow‐up was 7.0 (±6.2) years; 49.4% had one or more relapse. Patients positive for ANCA more commonly had neurological and kidney involvement when compared with patients negative for ANCA, who had more cardiac and lung manifestations. At last study visit, only 35 (12.6%) patients had been off all therapy for more than 2 years during their follow‐up. The overall mortality rate was 4.0% and did not differ by ANCA status or cyclophosphamide use. Scores on the Vasculitis Damage Index (VDI) for 134 patients with two or more visits and more than 1 year of follow‐up increased from 1.7 (±1.8) at enrollment (3.7 [±5.1] years after diagnosis) to 3.35 (±2.1) at last follow‐up (7.5 [±5.8] years after diagnosis), mainly represented by chronic asthma (67.5%), peripheral neuropathy (49.6%), and chronic sinusitis (31.3%). Longer duration of glucocorticoid use and relapse were associated with higher VDI scores.ConclusionThis analysis describes the many clinical manifestations and varied outcomes of EGPA and highlights the ongoing need to attain more sustained, long‐term remission to limit the accrual of disease‐related damage.
Challenges in the Treatment of Restless Legs Syndrome: A Case Report
Umbreit, Audrey , Sinha, Shirshendu , Kolla, Bhanu Prakash , Mansukhani, Meghna P , Mansukhani, Meghna P.

Mayo Clinic

Journal of Primary Care & Community Health | May 25, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211019590 | PMID 34032164 Get It

Treatment resistant restless legs syndrome (RLS) in the setting of psychiatric comorbidities can be difficult to manage. Our patient is a 69-year-old Caucasian gentleman with bipolar disorder type I, unspecified anxiety disorder, obstructive sleep apnea (OSA), and treatment-refractory RLS. At initial presentation, the patient’s prescribed medication regimen included fluoxetine 40 mg daily, gabapentin 800 mg in the morning and 3200 mg at bedtime, pramipexole 0.375 mg daily, lamotrigine 200 mg daily, trazodone 200 mg at bedtime, and temazepam 15 to 30 mg as needed for insomnia and RLS. Over the course of nearly 4 years, treatment interventions for this patient’s RLS included: cognitive behavioral therapy for insomnia, discontinuation of exacerbating medications, switching dopamine agonists, use of pregabalin and iron supplement. This report demonstrates a challenging case of RLS in the setting of psychiatric comorbidities, development of augmentation, and polypharmacy.
Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19
Bierle, Dennis M. , Wilker, Caroline G. , Hanson, Sara N. , Moehnke, Darcie E. , Jackson, Tammy A., Ramar, Priya , Rosedahl, Jordan K., Philpot, Lindsey M. , Ganesh, Ravindra , Moehnke, Darcie E , Philpot, Lindsey M , Razonable, Raymund R.

Mayo Clinic

Journal of Primary Care & Community Health | May 25, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211019282 | PMID 34032171 Get It

Background The clinical outcomes of patients who decline anti-spike monoclonal antibody therapies for coronavirus disease-2019 (COVID-19) is not known. Factors associated with the decision to accept or decline the offer for anti-spike monoclonal antibody therapies are not established. This study aimed to identify factors impacting the decision to consent for monoclonal antibody therapies and assess the differences in clinical outcomes of patients who accepted compared to those who declined these therapies. Methods This retrospective cohort study enrolled 2820 adult patients who were offered monoclonal antibody therapies, bamlanivimab and casirivimab-imdevimab, for COVID-19 at Mayo Clinic in the Midwest between 11/19/2020 and 12/31/2020. The primary endpoint is the decision to accept or decline monoclonal antibody treatment. Secondary endpoints were patient-level factors that could have impacted the decision to accept treatment (age, gender, race, ethnicity, primary language spoken, and medical comorbidities). The main clinical endpoint was hospitalization within 28 days of COVID-19 diagnosis. Results 59.1% (n = 1669) chose to accept monoclonal antibody therapy, and 40.9% (n = 1151) chose to decline the offer for treatment. Patients were more likely to accept treatment if they were non-Hispanic White, English speaking, identified a spouse or life partner, had a religious affiliation, and possessed more medical comorbidities. Overall, 28-day hospitalization rate was 2.6% (n = 72/2820) and was higher among those who declined (3.3%) than those who accepted monoclonal antibody therapy (2.0%; Rate Ratio = 0.62, 95% Confidence Interval, 0.39-0.98). Conclusions Despite having more comorbidities, patients who accepted monoclonal antibody treatments had a lower rate of hospitalization compared to patients who declined treatment. Several social and cultural factors were associated with the decision to decline therapy, including race, language, ethnicity, and lack of social support. These findings can inform public health efforts to reduce social disparities in the treatment of COVID-19 and increase utilization of monoclonal antibody therapies in high risk populations.
Accuracy of Wearable Sensor Technology in Hand Goniometry: A Systematic Review
Ávila, Francisco R. , Carter, Rickey E. , Giardi, Davide , Guliyeva, Günel , Forte, Antonio J. , Bruce, Charles J. , Giardi, Davide , Forte, Antonio Jorge , Carter, Rickey E , Avila, Francisco R , McLeod, Christopher J.

Mayo Clinic

HAND | May 25, 2021 | Volume: 18 | Issue: 2 | Pages: 340-348

10.1177/15589447211014606 | PMID 34032154 Get It

Background Wearable devices and sensor technology provide objective, unbiased range of motion measurements that help health care professionals overcome the hindrances of protractor-based goniometry. This review aims to analyze the accuracy of existing wearable sensor technologies for hand range of motion measurement and identify the most accurate one. Methods We performed a systematic review by searching PubMed, CINAHL, and Embase for studies evaluating wearable sensor technology in hand range of motion assessment. Keywords used for the inquiry were related to wearable devices and hand goniometry. Results Of the 71 studies, 11 met the inclusion criteria. Ten studies evaluated gloves and 1 evaluated a wristband. The most common types of sensors used were bend sensors, followed by inertial sensors, Hall effect sensors, and magnetometers. Most studies compared wearable devices with manual goniometry, achieving optimal accuracy. Although most of the devices reached adequate levels of measurement error, accuracy evaluation in the reviewed studies might be subject to bias owing to the use of poorly reliable measurement techniques for comparison of the devices. Conclusion Gloves using inertial sensors were the most accurate. Future studies should use different comparison techniques, such as infrared camera–based goniometry or virtual motion tracking, to evaluate the performance of wearable devices.